Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients

Am J Hematol. 2022 Aug;97(8):E321-E324. doi: 10.1002/ajh.26629. Epub 2022 Jun 24.

Marco Salvini¹, Camilla Damonte², Lorenzo Mortara³, Fabrizio Maggi^{1

2}, Antonino Bruno^{3

4}, Giacomo Pellegrini^{1

5}, Barbara Mora^{1

2}, Marco Brociner¹, Alessia Ingrassia¹, Roberta Mattarucchi¹, Benedetta Bianchi¹, Davide Sirocchi¹, Stefania Agnoli¹, Elisa Rumi^{6

7}, Michele Merli¹, Alessandro Fossati¹, Susanna Bassi¹, Raffaella Bombelli³, Matteo Gallazzi³, Oscar Borsani⁷, Andreina Baj^{1

2}, Matteo Franchi^{5

8}, Paolo A Grossi^{1

2}, Francesco Passamonti^{1

2}

¹ ASST Sette Laghi, Ospedale di Circolo, Varese, Italy.
² Department of Medicine and Surgery, University of Insubria, Varese, Italy.
³ Laboratory of Immunology and General Pathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
⁴ IRCCS MultiMedica, Milan, Italy.
⁵ National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy.
⁶ Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
⁷ Department of Molecular Medicine, University of Pavia, Pavia, Italy.
⁸ Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.

No abstract available

Publication types